Neoadjuvant immunotherapy in a locally advanced colon cancer patient with MSI-H and suspected Lynch syndrome: A case report
Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · 1379-1383
DOI: 10.1055/a-2258-8565 ↗Kurz gefasst
Fallbericht in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von Xiaoyun Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anorectal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Microsatellite Instability, Colonic Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Carrilizumab, a PD-1 inhibitor, has shown therapeutic effectiveness in patients with late-stage or metastatic solid tumors exhibiting DNA mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). dMMR/MSI-H cancer patients are known to be responsive to PD-1 inhibitors. However, the use of carrilizumab for preoperative immunotherapy in early, unresectable MSI-H/dMMR primary colon cancer lesions is relatively underexplored. We present the case of a 46-year-old male who sought medical attention at our institution due to a history of hematochezia for two weeks, right-sided abdominal pain for one week, and loose stools. Imaging indicated duodenal involvement, and a biopsy confirmed ascending colon adenocarcinoma with MSI-H status. Given that the patient’s family exhibited a history of more than three confirmed cases of colorectal cancer spanning two generations, Lynch syndrome was considered. After four cycles of PD-1 antagonist immunotherapy with carrilizumab, the patient’s symptoms resolved, and physical examination revealed no abdominal tenderness or palpable masses. Following radical colectomy, the primary tumor exhibited a pathological complete response. This case highlights the potential of preoperative neoadjuvant immunotherapy to improve staging accuracy and increase surgical resection rates in T4b MSI-H colon cancer patients without distant metastasis, suggesting a need for reconsideration of the treatment approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Anorectal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- Department of Pathology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- Guiyang Public Health Clinical Center, Guiyang, China.
Zitieren
APA
Li, X., Xiang, Y., Zhen, Y., & Yu, Y. (2024). Neoadjuvant immunotherapy in a locally advanced colon cancer patient with MSI-H and suspected Lynch syndrome: A case report. Zeitschrift für Gastroenterologie, 62(09), 1379-1383. https://doi.org/10.1055/a-2258-8565
Vancouver
Li X, Xiang Y, Zhen Y, Yu Y. Neoadjuvant immunotherapy in a locally advanced colon cancer patient with MSI-H and suspected Lynch syndrome: A case report. Zeitschrift für Gastroenterologie. 2024;62(09):1379-1383. doi:10.1055/a-2258-8565
BibTeX
@article{Li2024,
author = {Li, Xiaoyun and Xiang, Yining and Zhen, Yunhuan and Yu, Yong},
title = {Neoadjuvant immunotherapy in a locally advanced colon cancer patient with MSI-H and suspected Lynch syndrome: A case report},
journal = {Zeitschrift für Gastroenterologie},
year = {2024},
volume = {62},
number = {09},
pages = {1379--1383},
doi = {10.1055/a-2258-8565}
}
EUVIMED